Ironwood Total Assets from 2010 to 2026

IRWD Stock

USD 4.44 0.15 3.27%

Ironwood Pharmaceuticals' Total Assets are increasing over the years with slightly volatile fluctuation. Overall, Total Assets are expected to go to about 493.2 M this year. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2007-12-31

Previous Quarter

342.9 M

Current Value

396.1 M

Quarterly Volatility

265.6 M

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Interest Hikes

Check Ironwood Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ironwood Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.7 M, Interest Expense of 20.1 M or Total Revenue of 227.9 M, as well as many indicators such as Price To Sales Ratio of 2.19, Dividend Yield of 0.0 or Days Sales Outstanding of 139. Ironwood financial statements analysis is a perfect complement when working with Ironwood Pharmaceuticals Valuation or Volatility modules.

Build AI portfolio with Ironwood Stock

Check out the analysis of Ironwood Pharmaceuticals Correlation against competitors.

For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.

Analyzing Ironwood Pharmaceuticals's Total Assets over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Total Assets has evolved provides context for assessing Ironwood Pharmaceuticals's current valuation and future prospects.

Latest Ironwood Pharmaceuticals' Total Assets Growth Pattern

Below is the plot of the Total Assets of Ironwood Pharmaceuticals over the last few years. Total assets refers to the total amount of Ironwood Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Ironwood Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Ironwood Pharmaceuticals' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ironwood Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 350.91 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Ironwood Total Assets Regression Statistics

	Arithmetic Mean	491,885,285
	Geometric Mean	425,610,163
	Coefficient Of Variation	57.10
	Mean Deviation	208,383,841
	Median	403,544,200
	Standard Deviation	280,879,877
	Sample Variance	78893.5T
	Range	991M
	R-Value	0.44
	Mean Square Error	67833.1T
	R-Squared	0.19
	Significance	0.08
	Slope	24,494,839
	Total Sum of Squares	1262296.1T

Ironwood Total Assets History

	2026	493.2 M
	2025	403.5 M
	2024	350.9 M
	2023	471.1 M
	2022	1.1 B
	2021	1.1 B
	2020	559.2 M

Other Fundumenentals of Ironwood Pharmaceuticals

Intangibles To Total Assets

Ironwood Pharmaceuticals Total Assets component correlations

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Short Long Term Debt	Long Term Investments	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.69	0.2	-0.22	-0.11	-0.31	0.35	0.61	0.38	0.94	0.29	0.49	-0.2	0.32	0.55	0.59	0.1	0.44	-0.27	0.32	0.72	0.04
Total Stockholder Equity	0.69		0.46	-0.82	0.51	-0.05	-0.37	0.03	-0.35	0.77	-0.02	0.06	0.38	-0.07	-0.1	-0.02	0.05	-0.1	0.14	0.53	0.86	-0.38
Current Deferred Revenue	0.2	0.46		-0.51	0.4	-0.34	-0.37	-0.06	-0.31	0.29	0.13	-0.2	0.24	-0.01	-0.3	-0.17	-0.15	-0.3	0.03	0.58	0.41	-0.06
Net Debt	-0.22	-0.82	-0.51		-0.8	-0.08	0.76	0.32	0.7	-0.39	0.22	0.4	-0.48	0.32	0.53	0.46	0.01	0.49	-0.32	-0.46	-0.69	0.55
Retained Earnings	-0.11	0.51	0.4	-0.8		0.16	-0.85	-0.68	-0.79	0.0	-0.29	-0.76	0.48	-0.19	-0.84	-0.82	0.04	-0.48	0.45	0.48	0.37	-0.41
Accounts Payable	-0.31	-0.05	-0.34	-0.08	0.16		-0.44	-0.47	-0.25	-0.37	-0.06	-0.15	0.58	-0.65	-0.32	-0.38	0.63	0.05	0.72	-0.12	-0.38	-0.5
Long Term Debt	0.35	-0.37	-0.37	0.76	-0.85	-0.44		0.71	0.82	0.23	0.17	0.7	-0.68	0.55	0.87	0.84	-0.12	0.61	-0.64	-0.31	-0.1	0.67
Net Receivables	0.61	0.03	-0.06	0.32	-0.68	-0.47	0.71		0.79	0.52	0.45	0.64	-0.7	0.35	0.86	0.89	-0.17	0.52	-0.61	-0.15	0.22	0.3
Total Liab	0.38	-0.35	-0.31	0.7	-0.79	-0.25	0.82	0.79		0.18	0.46	0.59	-0.7	0.35	0.87	0.8	0.13	0.69	-0.42	-0.34	-0.24	0.4
Total Current Assets	0.94	0.77	0.29	-0.39	0.0	-0.37	0.23	0.52	0.18		0.17	0.41	-0.13	0.23	0.44	0.51	-0.01	0.18	-0.27	0.4	0.84	-0.02
Short Term Debt	0.29	-0.02	0.13	0.22	-0.29	-0.06	0.17	0.45	0.46	0.17		0.23	-0.13	0.31	0.24	0.29	-0.16	0.07	-0.35	-0.06	-0.22	-0.07
Common Stock	0.49	0.06	-0.2	0.4	-0.76	-0.15	0.7	0.64	0.59	0.41	0.23		-0.13	0.25	0.82	0.84	-0.04	0.46	-0.41	-0.23	0.06	0.35
Property Plant Equipment	-0.2	0.38	0.24	-0.48	0.48	0.58	-0.68	-0.7	-0.7	-0.13	-0.13	-0.13		-0.48	-0.58	-0.54	0.2	-0.44	0.6	0.25	0.0	-0.45
Net Tangible Assets	0.32	-0.07	-0.01	0.32	-0.19	-0.65	0.55	0.35	0.35	0.23	0.31	0.25	-0.48		0.26	0.31	-0.6	0.17	-0.81	-0.01	0.11	0.64
Long Term Debt Total	0.55	-0.1	-0.3	0.53	-0.84	-0.32	0.87	0.86	0.87	0.44	0.24	0.82	-0.58	0.26		0.96	0.07	0.64	-0.46	-0.26	0.07	0.38
Capital Surpluse	0.59	-0.02	-0.17	0.46	-0.82	-0.38	0.84	0.89	0.8	0.51	0.29	0.84	-0.54	0.31	0.96		-0.07	0.54	-0.54	-0.22	0.16	0.45
Deferred Long Term Liab	0.1	0.05	-0.15	0.01	0.04	0.63	-0.12	-0.17	0.13	-0.01	-0.16	-0.04	0.2	-0.6	0.07	-0.07		0.43	0.76	0.08	-0.15	-0.37
Short Long Term Debt	0.44	-0.1	-0.3	0.49	-0.48	0.05	0.61	0.52	0.69	0.18	0.07	0.46	-0.44	0.17	0.64	0.54	0.43		-0.03	-0.04	-0.01	0.25
Long Term Investments	-0.27	0.14	0.03	-0.32	0.45	0.72	-0.64	-0.61	-0.42	-0.27	-0.35	-0.41	0.6	-0.81	-0.46	-0.54	0.76	-0.03		0.28	-0.13	-0.58
Net Invested Capital	0.32	0.53	0.58	-0.46	0.48	-0.12	-0.31	-0.15	-0.34	0.4	-0.06	-0.23	0.25	-0.01	-0.26	-0.22	0.08	-0.04	0.28		0.51	-0.1
Net Working Capital	0.72	0.86	0.41	-0.69	0.37	-0.38	-0.1	0.22	-0.24	0.84	-0.22	0.06	0.0	0.11	0.07	0.16	-0.15	-0.01	-0.13	0.51		-0.1
Capital Stock	0.04	-0.38	-0.06	0.55	-0.41	-0.5	0.67	0.3	0.4	-0.02	-0.07	0.35	-0.45	0.64	0.38	0.45	-0.37	0.25	-0.58	-0.1	-0.1

Click cells to compare fundamentals

About Ironwood Pharmaceuticals Financial Statements

Ironwood Pharmaceuticals stakeholders use historical fundamental indicators, such as Ironwood Pharmaceuticals' Total Assets, to determine how well the company is positioned to perform in the future. Although Ironwood Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Ironwood Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Ironwood Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Ironwood Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Total Assets	403.5 M	493.2 M
Intangibles To Total Assets	0.01	0.01

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

FSLY	Fastly Class A
MOB	Mobilicom Limited American
CMG	Chipotle Mexican Grill

When determining whether Ironwood Pharmaceuticals is a strong investment it is important to analyze Ironwood Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ironwood Pharmaceuticals' future performance. For an informed investment choice regarding Ironwood Stock, refer to the following important reports:

How To Invest In Ironwood

Details

Is Ironwood Stock a good investment?

Details

What is Ironwood Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Ironwood Pharmaceuticals Correlation against competitors.

For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.

You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Will Biotechnology sector continue expanding? Could Ironwood diversify its offerings? Factors like these will boost the valuation of Ironwood Pharmaceuticals. Market participants price Ironwood higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Ironwood Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.

Quarterly Earnings Growth

10.468

Earnings Share

0.18

Revenue Per Share

2.103

Quarterly Revenue Growth

0.333

Return On Assets

0.2288

Investors evaluate Ironwood Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Ironwood Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Ironwood Pharmaceuticals' market price to deviate significantly from intrinsic value.

Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Ironwood Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Ironwood Total Assets from 2010 to 2026

Latest Ironwood Pharmaceuticals' Total Assets Growth Pattern

Ironwood Total Assets Regression Statistics

Ironwood Total Assets History

Other Fundumenentals of Ironwood Pharmaceuticals

Ironwood Pharmaceuticals Total Assets component correlations

About Ironwood Pharmaceuticals Financial Statements

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY